Agios Reports FDA Approval Of Supplemental New Drug Application For TIBSOVO As Monotherapy for Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy